Read more about the article Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients
Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients

Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients

Lonvo-z showed a 98% reduction in HAE attacks for 10 patients over three-year follow-up, demonstrating promising safety and efficacy.Quiver AI SummaryIntellia Therapeutics has announced promising three-year follow-up data from its…

Continue ReadingIntellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients
Read more about the article Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug
Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug

Upstream Bio presents data suggesting verekitug offers greater potency than tezepelumab in targeting inflammatory diseases.Quiver AI SummaryUpstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology…

Continue ReadingUpstream Bio Presents Pharmacology Modeling Data Supporting Verekitug
Read more about the article Celldex Therapeutics Reports 77% Angioedema-Free Rate at Week 52 in Phase 2 Trial of Barzolvolimab for Chronic Spontaneous Urticaria
Celldex Therapeutics Reports 77% Angioedema-Free Rate at Week 52 in Phase 2 Trial of Barzolvolimab for Chronic Spontaneous Urticaria

Celldex Therapeutics Reports 77% Angioedema-Free Rate at Week 52 in Phase 2 Trial of Barzolvolimab for Chronic Spontaneous Urticaria

Barzolvolimab significantly reduced angioedema symptoms in CSU patients after 52 weeks, demonstrating clinical efficacy and improved quality of life.Quiver AI SummaryCelldex Therapeutics has announced promising results from its Phase 2…

Continue ReadingCelldex Therapeutics Reports 77% Angioedema-Free Rate at Week 52 in Phase 2 Trial of Barzolvolimab for Chronic Spontaneous Urticaria
Read more about the article Jasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible Urticaria
Jasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible Urticaria

Jasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible Urticaria

Jasper Therapeutics reports promising SPOTLIGHT study results for briquilimab in treating chronic inducible urticaria with favorable safety outcomes.Quiver AI SummaryJasper Therapeutics, Inc. announced promising results from the 180mg cohort of…

Continue ReadingJasper Therapeutics Reports Encouraging Results from SPOTLIGHT Phase 1b/2a Study of Briquilimab for Chronic Inducible Urticaria

End of content

No more pages to load